Samsung Biologics Co.,Ltd. (KRX: 207940)

Samsung Biologics Co.,Ltd. Revenue

Samsung Biologics Co.,Ltd. had revenue of 1.16T KRW in the quarter ending June 30, 2024, with 33.56% growth. This brings the company's revenue in the last twelve months to 4.21T, up 22.93% year-over-year. In the year 2023, Samsung Biologics Co.,Ltd. had annual revenue of 3.69T with 23.10% growth.

• Revenue (ttm): 4,211.29B
• Revenue Growth: +22.93%
• P/S Ratio: 17.51
• Revenue / Employee: 931.08M
• Employees: 4,523
• Market Cap: 73.74T

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	3,694.59B	693.29B	23.10%
Dec 31, 2022	3,001.30B	1,433.29B	91.41%
Dec 31, 2021	1,568.01B	403.23B	34.62%
Dec 31, 2020	1,164.78B	463.19B	66.02%
Dec 31, 2019	701.59B	165.79B	30.94%